

Bridge is the first FDA-cleared, drug-free, non-surgical device to use neuromodulation to aid in the reduction of symptoms associated with opioid withdrawal.

In a study of 73 adult patients with opioid use disorder, a reduction in opioid withdrawal symptoms was observed when Bridge was used during active withdrawal. The study demonstrated Bridge to be:

### **FAST**

> Provides symptom relief in as little as 20 minutes<sup>1</sup>

### **EFFECTIVE**

- > May reduce opioid withdrawal symptoms
- > Helps users successfully make treatment progress:
  - 88% of patients successfully transitioned into a medically assisted therapy (MAT) program<sup>1</sup>

### SAFE<sup>2</sup>

- > No reported side effects with minimal risks during device placement
  - < 0.17% Incidence of significant pain at the lead implantation site
  - < 0.91% Incidence of bleeding at the lead implantation site
  - < 0.91% Incidence of dermatitis at the lead implantation site
  - 0% Incidence of syncope


### Mean Clinical Opioid Withdrawal Scale (COWS) Scores While Using Masimo Bridge During Withdrawal





## What is Bridge?

Bridge is a small electrical nerve stimulator device that contains a battery-powered chip and wires that are applied around a patient's ear. It requires a prescription and is offered to qualified healthcare professionals with training. The Bridge kit includes everything needed to apply the device.



# Who Can Bridge Help?

Bridge can be used for patients\* experiencing opioid withdrawal symptoms, while undergoing treatment for opioid use disorder, when:


- Initiating treatment
- Transitioning to naltrexone
- Tapering off medication-assisted treatment

# **Specifications**

### **Ordering Information**

Masimo Part Number . . . . .

Miranda A et al. Am J Drug Alcohol Abuse . 2018;44(4):498]. Am J Drug Alcohol Abuse . 2018;44(1):56-63. doi:10.1080/00952990.2017.1295459. Roberts A et al. Minimal adverse effects profile following implantation of periauricular percutaneous electrical nerve field stimulators: a retrospective cohort study. Medical Devices (Auckland, N.Z.) vol. 9 389-393. 3 Nov. 2016, doi:10.2147/MDER.S107426





<sup>\*</sup> Contraindications: Use of cardiac pacemakers, hemophilia, psoriasis vulgaris.